Resveratrol Prevents β-cell Dedifferentiation in Non-Human Primates Given a High Fat/High Sugar Diet

Running Title: Resveratrol Reverses the Effect of HFS Diets

Jennifer L. Fiori¹, Yu-Kyong Shin¹,², Wook Kim¹,³, Susan M. Krzysik-Walker¹, Isabel González-Mariscal¹, Olga D. Carlson¹, Mitesh Sanghvi¹, Ruin Moaddel¹, Kathleen Farhang¹, Shekhar K. Gadkaree¹, Maire E. Doyle⁴, Kevin J. Pearson⁵,⁶, Julie A. Mattison⁵, Rafael de Cabo⁵, and Josephine M. Egan¹

¹Laboratory of Clinical Investigation and ⁵Translational Gerontology Branch, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA, ²Biochemistry Department, Boston University School of Medicine, Boston, MA, USA, ³Department of Molecular Science and Technology, Ajou University, Suwon, Republic of Korea, ⁴Division of Endocrinology, Johns Hopkins Bayview Medical Center, Baltimore, MD, USA, and ⁶Graduate Center for Nutritional Sciences, University of Kentucky College of Medicine, Lexington, KY, USA

Correspondence should be addressed to:
Josephine M. Egan, M.D.
National Institute on Aging
251 Bayview Boulevard, Suite 100
Baltimore, MD 21224
Tel: (410) 558-8414
Fax: (410) 558-8381
ABSTRACT

Eating a ‘Westernized’ diet high in fat and sugar leads to weight gain and numerous health problems, including the development of type 2 diabetes mellitus (T2DM). Rodent studies have shown that resveratrol supplementation reduces blood glucose, preserves β-cells in islets of Langerhans, and improves insulin action. While rodent models are helpful for understanding β-cell biology and certain aspects of T2DM pathology, they fail to reproduce the complexity of the human disease as well as non-human primates. Rhesus monkeys were fed a standard diet (SD), or a high fat/ high sugar diet in combination with either placebo (HFS) or resveratrol (HFS+Resv) for 24 months and pancreata were examined before overt dysglycemia occurred. Increased glucose-stimulated insulin secretion and insulin resistance occurred in both HFS and HFS+Resv diets compared to SD. While islet size was unaffected, there was a significant decrease in β-cells and increase in α-cells, containing glucagon and GLP-1, with HFS diets. Islets from HFS+Resv monkeys were morphologically similar to SD. HFS diets also resulted in decreased expression of essential β-cell transcription factors, FOXO1, NKX6-1, NKX2-2, and PDX1 which did not occur with resveratrol supplementation. Similar changes were observed in human islets where the effects of resveratrol were mediated through SIRT1. These findings have implications for the management of humans with insulin resistance, pre-diabetes, and diabetes.
INTRODUCTION

In many developing countries, a rapid nutritional transition has occurred from a healthy diet high in fiber and low in fat and calories to calorie-dense meals containing refined carbohydrates, red meats, sugary desserts and drinks, and high fat foods (1). When ‘Westernized’ diets are introduced, the population responds with weight gain leading to numerous health problems, including hypertension, coronary artery disease and strokes, respiratory effects, cancers, reproductive abnormalities, and type 2 diabetes mellitus (T2DM) (2). Obesity, a result of sedentary lifestyles and ‘Westernized’ diets, has reached epidemic proportions and is the major risk factor for developing T2DM.

Currently 25.8 million Americans have adult-onset or T2DM and an additional 79 million exhibit a metabolic profile which is considered a precursor to T2DM (3). Several years ago the Diabetes Prevention Program Trial (DPPT), targeting persons with pre-diabetes, found the incidence of T2DM reduced by 31% with metformin and 58% with lifestyle interventions, including exercise and weight reduction, over an average follow up of 2.8 years (4). However, in absolute terms, metformin had only a minor impact on the transition to diabetes, with 13 out of every 14 individuals taking metformin going on to develop diabetes. Although lifestyle intervention in a highly controlled setting faired twice as well, long term modification of diet and activity patterns are very difficult for most adults to achieve. Further, despite the findings from the DPPT and recommendations for people with pre-diabetes to use metformin, lose weight, and start an exercise regimen, rates of diabetes continue to escalate. Therefore, it is extremely important to investigate the metabolic and physiologic alterations that occur in pre-diabetic states and elucidate the underlying etiopathology in order to develop effective strategies to prevent the transition to T2DM.
In the last several years, rodent studies and experiments in vitro have provided evidence that resveratrol, a naturally occurring phytoalexin found in numerous plant species, exerts beneficial effects in organisms and may be helpful in preventing some metabolic diseases, including diabetes (5). In animals given a high fat diet, resveratrol has been shown to increase their survival and motor function (6), reduce visceral fat and liver mass indexes (7), and induce beneficial changes in lipid parameters (8). In addition, several different rodent models of diabetes have shown that resveratrol can reduce blood glucose (9), preserve β-cells (10), and improve insulin action (6). However, limited human data on resveratrol’s metabolic effects are more controversial. A few studies report that resveratrol improves insulin sensitivity in adults who are obese (11), have T2DM (12), or have impaired glucose tolerance (13), while other studies support that resveratrol supplementation does not improve metabolic function in non-obese women (14) or in obese men (15).

While rodent models are helpful for understanding β-cell biology and some aspects of the pathogenesis of T2DM, they cannot reproduce the complexity of the human disease as well as non-human primates. T2DM occurs spontaneously in ad libitum-fed non-human primates (16). Also, monkey and human endocrine pancreata are similar with β- and α-cells interspersed, unlike rodent islets, and with similar islet size and cellular distribution of islet cell types (17). The metabolic and hormonal changes observed in humans with insulin resistance, pre-diabetes, and diabetes also occur in monkeys (18,19). Therefore, monkeys serve as ideal models for studying islets as they likely display evolving changes in response to increased insulin requirement. Additionally, these changes occur within a reasonable time frame of experimentation (18). We undertook a long-term study of monkeys given a high fat/ high sugar (HFS) diet to evaluate changes in islet function and morphology resulting from unremitting increased insulin
requirement in the absence of dysglycemia and whether these changes were mitigated by resveratrol.
RESEARCH DESIGN AND METHODS

Animals. Twenty-four adult male rhesus monkeys (*Macaca mulatta*) were housed continuously at the NIH Animal Center (Poolesville, MD). The animal center is fully accredited by the American Association for Accreditation of Laboratory Animal Care, and all procedures were approved by the Animal Care and Use Committee of the NIA Intramural Program.

Diet. During baseline assessments, all monkeys were maintained on standard NIH monkey chow (Purina Mills, St. Louis, MO). After baseline assessment, they were randomized into one of three groups: a healthy standard diet (SD, 4 monkeys) or a high fat/high sugar diet in combination with either placebo (HFS, 10 monkeys) or resveratrol (HFS+Resv, 10 monkeys). SD was a purified diet consisting of 13% of kcal in fat and less than 5% sucrose by weight. The HFS diet was a specially formulated purified ingredient diet with 42% of kcal in fat and approximately 27% sucrose by weight (Harlan, Teklad, Indianapolis, IN). The monkeys were gradually switched to the HFS diet over a 3 week period. Monkeys received 2 meals per day at estimated *ad libitum* levels throughout the study and water was always available. The average food consumption for weekly periods was the same for all 3 groups.

Resveratrol dosing. Resveratrol was supplied by DSM Nutritional Products North America (Parsippany, NJ). The dose for monkeys was derived from the protective dose reported in mice (22 mg/kg) (6) and adjusted by allometric scaling to an average monkey body weight of 12.1 kg. The monkey equivalent dose was determined to be 40.7 mg. The resveratrol was used to formulate a flavored primate treat (Bio-Serve, Frenchtown, NJ) that was given to the monkeys prior to each meal. Thus, the monkeys received a total dose of 80 mg per day for the first year,
and the resveratrol dose was increased to 240 mg twice a day during the second year. Monkeys in non-resveratrol groups received a cherry flavored placebo treat (sugar pill) that was identical in looks and taste to the resveratrol treats.

**Serum resveratrol levels.** The extraction of resveratrol and its metabolites was performed with modifications of a previously published method (20). Briefly, 90 µl of methanol and 10 µl of hexestrol (internal standard) were added to 100 µl of serum, which was vortexed and centrifuged at 20,800 rcf for 10 min at 4°C. The supernatant was transferred to an autosampler vial for further analysis. The chromatographic separation of resveratrol and its metabolites was carried out on a Shimadzu Prominence HPLC system (Columbia, MD). The samples were introduced to the analytical column in 20 µl injections using a Shimadzu SIL 20A autosampler which was maintained at 4°C. The separation of resveratrol, resveratrol-3-O-sulfate, resveratrol-3-O-glucoronide and resveratrol-4’-O-glucuronide was accomplished using an Eclipse XDB-C18 guard column (4.6 mm x 12.5 mm) and a Discovery C18 column (150 x 4.6 mm ID, 5 µm). The mobile phase consisted of water containing 0.1% acetic acid and 0.07% triethylamine as component A and acetonitrile as component B. A linear gradient was run as follows: 0-3 min 20% B; 3-25 min 20-60% B; 25-30 min 60-20% B at a flow rate of 1.0 ml/min. MS/MS analysis was performed using API4000 system from Applied Biosystems with Turbo Ion Spray® (Foster City, CA). The data was acquired and analyzed using Analyst version1.4.2. Negative electrospray ionization data were acquired using the following MRM transitions: resveratrol (227-185); resveratrol –sulfate (307-227); resveratrol-glucoronide (403-227) and hexestrol (269-134). The TIS instrumental source settings for temperature (500°C), curtain gas (10 psi), IS1 (60 psi), IS2 (70 psi), entrance potential (-10V) and ion spray voltage (-4500V). The TIS compound
parameter settings for declustering potential, collision energy, and collision cell exit potential were -70V, -25V, -7V for resveratrol; -50V, -28V and -9V for resveratrol metabolites and -82V, -20V and -8V for hexesterol.

**Hormone assays.** Intravenous glucose challenge (IVG) was performed with 300 mg/kg of a 50% dextrose solution (Hospire, Inc., Lake Forest, IL). Blood samples were obtained by venipuncture of the femoral vein using a vacutainer and vacuum tubes. Glucose was measured in whole blood using the Ascensia Elite glucose meter (Bayer, Mishawaka, IN). Serum glucagon was measured by RIA (Millipore, Billerica, MA) and serum insulin and media from human islets by ELISA (Mercodia, Uppsala, Sweden) according to the manufacturers’ instructions. The insulin area under the curve (AUC) was determined using GraphPad Prism (La Jolla, CA). The insulin sensitivity index (ISI) was calculated as previously described (21).

**Immunofluorescence and densitometry.** Dr. Frederic B. Askin from the Department of Pathology at The Johns Hopkins University School of Medicine (Baltimore, MD) provided anonymous human pancreas in paraffin blocks. Pancreata from 2 diabetic monkeys in a separate cohort were procured when animals were euthanized for medical reasons. Our monkeys were fasted overnight and following blood draw and euthanasia, the pancreata were excised. Human islets were provided by the NIDDK-funded Integrated Islet Distribution Program (IIDP) at City of Hope and were embedded in Histogel (Thermo Scientific, Waltham, MA) following treatment. Both human islets and monkey pancreata were fixed in 4% paraformaldehyde, embedded in paraffin blocks, and sectioned (5 µm). After deparaffinization, sections were treated with antigen retrieval solution (BioGenex, Fremont, CA), washed, permeabilized, blocked, and primary
antibodies were added overnight at 4°C as follows: Insulin (1:200; Millipore or Sigma, St. Louis, MO), Glucagon (1:500; Millipore or Sigma), PC1/3 (1:200; Provided by Dr. Donald Steiner at The University of Chicago, IL), GLP-1 (1:100; Sigma or US Biological, Swampscott, MA), Ki-67 (1:50; Dako, Carpinteria, CA), FOXO1 (1:100; Cell Signaling, Danvers, MA), Pancreatic Polypeptide (1:200; Millipore), Somatostatin, Phospho-IR, and Phospho-Bad (Serine<sup>136</sup>) (1:100; Santa Cruz Biotechnology, Santa Cruz, CA), and NKX2-2 and NKX6-1 (1:100; Novus Biologicals, Littleton, CO). After washing, sections were incubated with fluorescently labeled secondary antibodies (1:500; Rhodamine Red-X, FITC, Cy5, Jackson ImmunoResearch, West Grove, PA) with or without TO-PRO-3 (1:5000; Molecular Probes, Grand Island, NY) for nuclear staining. Imaging was performed at 40X using a Zeiss LSM-710 confocal microscope (Jena, Germany). Densitometry of staining was performed using ImageJ (NIH, Bethesda, MD). Images were separated by color, inverted to black and white, and the integrated density was calculated for each stain using the tracing function.

**Pancreatic islet size quantification.** Multiple images (200 µm apart) from each monkey were assessed for signal intensity. Islet sizing was performed using MATLAB's (MathWorks, Natick, MA) Image Processing Toolbox. Each islet was carefully isolated using the roipoly tracing function. The various immunostains were separated by color into variables for processing. The resulting total islet, α-cell, and β-cell sizes were calculated based on total traced size, percentage of glucagon immunostain, and percentage of insulin immunostain, respectively. Somatostatin and pancreatic polypeptide positive cells were sized similarly. The percentage of cells/islet was determined by counting the number of insulin, glucagon, and TO-PRO-3 positive cells in each diet intervention.
**Quantitative PCR.** RNA was extracted using TRIzol (Invitrogen, Grand Island, NY) and an RNeasy Mini kit (Qiagen, Valencia, CA) and cDNA was synthesized using qScript cDNA Supermix (Quanta Biosciences, Gaithersburg, MD). Gene expression in monkey islets was quantified using SYBR green (Quanta Biosciences) and values were compared to standard curves and normalized to 18S (Ambion Austin, TX). The monkey primers were: FOXO1 (F: 5'-GGATGTGCATTCTATGGTGTACC-3' and R: 5'-TTTCGGGATTGCTTATCTCAGAC-3'), NKX2-2 (F: 5'-CCGGGCCGAGAAAGGTATG-3' and R: 5'-GTGGCCGTTCCCTGACCAA-3'), NKX6-1 (F: 5'-ATCTTCTGGCCCGAGTGA-3' and R: 5'-CGCCAAGTATTTTGTTTGTTCG-3'), and PDX1 (F: 5'-CGGAACTTTCTATTTAGGATGTGG-3' and R: 5'-AAGATGTGAAGGTCATACTGGCTC-3') (Integrated DNA Technologies, Coralville, IA). Gene expression in human islets was quantified using TaqMan Fast Advanced Master Mix (Invitrogen) and normalized to Actin labeled with VIC. Human primers were labeled with FAM and purchased from Invitrogen (Taqman Gene Expression Assays). Quantitative PCR was performed on an ABI Prism 7300 (Applied Biosystems, Foster City, CA) detection system.

**GLP-1 secretion assay.** Islets were incubated in Dulbecco’s modified Eagle’s medium (DMEM; Gibco, Grand Island, NY) containing 5 mmol/L glucose (Sigma), 50 µM dipeptidyl pepsidease (DPP)-IV inhibitor (Millipore), and 3% BSA at 37°C with 5% CO₂ overnight. Islets were then washed with medium, separated into several dishes containing 20 islets each, and placed in fresh medium. The islets were then incubated for 1 h at 37°C, after which medium was collected and secreted GLP-1 levels were measured by ELISA (Alpco Diagnostics, Salem, NH). Levels were normalized to total protein content as determined by a BCA protein assay (Pierce, Rockford, IL).
**cAMP assay.** Human islets were prepared as described above. Total protein was extracted using lysis buffer (0.01M TrisHcl, 1% Triton X-100, 0.15M NaCl, 0.5mM EDTA, and protease and phosphatase inhibitor cocktails). GLP-1 levels were measured by ELISA to determine the amount in total protein, and the islet extract was diluted to yield the different concentrations of GLP-1 (22). Chinese hamster ovary (CHO)/K1 cells were stably transfected with rat GLP-1 Receptor (GLP-1R) as previously described (23). Both CHO/K1 and CHO/GLP-1R cells were treated with increasing concentrations (0 – 20 pM) of full length GLP-1 (Bachem, Torrance, CA) as well as GLP-1 islet extract for 30 min. After treatment, the cell supernatant was assayed using a Direct cAMP ELISA kit (Enzo Life Sciences, Farmingdale, NY) following the manufacturers’ protocol.

**Treatment of human islets.** Human islets were prepared as described above 1 day prior to experimentation. Islets were then separated into several dishes containing 100 islets into fresh medium supplemented with 3% BSA and 5 mM glucose for the control condition or 13 mM glucose and 500 µM sodium palmitate (Sigma) for the high fat/high sugar (HFS) condition. Islets incubated under HFS condition were also treated with 1 µM EX-527 and/or 1 nM resveratrol (TOCRIS Bioscience, Minneapolis, MN) for 24 hrs. Media was then collected for measuring insulin secretion and islets were processed for quantitative PCR and immunofluorescence as described above.

**Statistical analysis.** Quantitative data are represented as the mean ± SEM. Differences between mean values were compared statistically by one-way analysis of variance (ANOVA) followed by Bonferroni’s post hoc comparison. A p-value of <0.05 was considered statistically significant.
RESULTS

**Monkey assessment and hormone levels.** Adult male rhesus monkeys (average age at baseline was 10.5 ± 0.4 years) were fed a standard diet (SD), or a high fat/ high sugar diet in combination with either placebo (HFS) or resveratrol (HFS+Resv) for 24 months. Prior to euthanasia, the average serum concentrations of resveratrol and resveratrol-3-O-sulfate in HFS+Resv were 27.7±8.6 and 239.1±82.2 ng/ml, respectively, while the levels of resveratrol-4’-O-glucuronide and 3-O-glucuronide were below our quantitation limits: all were below detection levels in SD and HFS. SD monkeys gained very little weight, whereas HFS and HFS+Resv monkeys gained a significant amount over the 24-month period (Table 1). Based on fasting glucose and insulin levels at euthanasia, no metabolic dysregulation had occurred over 24 months within the feeding regimens (Table 1). All three groups had similar glucose levels following intravenous glucose challenge (IVG) both at baseline and after 24 months (Fig. 1A). However, in both HFS and HFS+Resv, the serum insulin levels and the insulin area under the curve (AUC) were significantly greater following IVG compared to baseline levels, consistent with weight gain and insulin resistance (Fig. 1B, Table 1). The insulin sensitivity index (ISI) of the SD animals was stable for the duration of the study, while both HFS and HFS+Resv animals exhibited decreased insulin sensitivity after 24 months on a HFS diet (Table 1). Fasting serum glucagon was not significantly altered over 24 months in any group (Table 1). Within all of these parameters, there was a lot of heterogeneity in the monkeys in response to the diet intervention, both at 0 and 24 months (Supplemental Fig. 1).

**A HFS diet resulted in morphological changes in islets that were prevented by resveratrol.**

On evaluating islet morphology, we found that while total islet size remained unchanged across
the groups (Fig. 1D), α-cell mass was significantly increased with HFS at the expense of the β-cell mass compared to SD, with heterogeneity amongst the HFS islets in their numbers of α- and β-cells (Fig. 1E-F). This caused a significant alteration in the ratio of α-/β-cell mass (Fig. 1G). The total number of α- and β-cells per islet was also counted and corroborated the α- and β-cell mass (Fig. 1H-I). The increase in α-cell mass did not occur with resveratrol treatment. HFS+Resv monkeys exhibited a significant decrease in α-cell mass and a lower ratio of α-/β-cell mass compared to SD. The islet changes in HFS were similar to those of 2 non-study rhesus monkeys from our colony that spontaneously developed T2DM, though the T2DM monkeys appeared to have even fewer β-cells (Fig. 1C, T2DM).

Lack of evidence for β-cell apoptosis or α-cell mitosis in islets from monkeys given a HFS diet. Since the change in the ratio of α-/β-cell numbers without dysglycemia was unexpected, we looked for β-cell apoptosis and α-cell mitosis. No detectable evidence of β-cell apoptosis was observed as we were unable to detect TUNEL stained nuclei or cleaved caspase 1 or 3 in ~2,000 islets. Additionally, expression of pro-survival protein, phosphorylated BAD, was similar in all three groups (Fig. 2A). Despite the obvious increase in α-cell numbers with HFS, no mitotic Ki-67 positive α-cells were found. Abundant Ki-67-positive cells were present in exocrine pancreas and small intestine (Fig. 2B). There were no differences in the numbers of somatostatin or pancreatic polypeptide islet cell types between diet interventions (Fig. 2C).

Resveratrol protected depletion of β-cell specific transcription factors by a HFS diet. Next we examined the effect of a HFS diet on insulin/insulin-like growth factor 1 (IGF-1) signaling and β-cell specific transcription factors. HFS islets exhibited decreased tyrosine phosphorylated
IR (P-IR; activated insulin receptor), including within the remaining β-cells (Fig. 3A-B). P-IR in SD and HFS+Resv was similar, indicating that resveratrol was protective of P-IR in islets. Loss of β-cell P-IR in rodents causes profound defects in β-cell growth (24,25). FOXO1 is a downstream effector in β-cells of IR signaling and total FOXO1 protein (Fig. 3C-D) and mRNA (Fig. 3E) was depleted in HFS islets. In β-cells of SD and HFS+Resv monkeys, total FOXO1 was similar. We next studied factors that are known to be affected by loss of FOXO1 and that are essential in maintaining β-cell phenotype (26). NKX6-1 is a transcriptional repressor that is tightly restricted to β-cell nuclei in adult islets and is known to suppress glucagon expression (27), and NKX2-2 is a transcriptional factor necessary for optimal insulin gene expression (28). Both NKX6-1 and NKX2-2 protein (Fig. 4A-B and 4D-E respectively) and mRNA (Fig. 4C and Fig. 4F respectively) were severely affected in HFS monkeys. Islets with the fewest number of β-cells had greatly diminished nuclear NKX6-1, with a gradient of decreased expression of NKX6-1 in β-cells of different HFS monkeys (Fig. 4A, bottom panel). Similarly, the mRNA levels of PDX1, a transcription factor necessary for pancreatic development and β-cell maturation (29), were also significantly down regulated in HFS monkeys (Fig. 4G). Resveratrol appeared to protect β-cells from loss of P-IR, FOXO1, NKX6-1, NKX2-2, and PDX1 thereby preserving β-cell mass in HFS+Resv monkeys.

Resveratrol protected human islets from HFS-induced changes in morphology and loss of β-cell specific transcription factors. Similar to observations in monkey islets following a HFS diet, when human islets were treated with high glucose and palmitate to mimic HFS conditions, the number of insulin positive β-cells was decreased and the number of glucagon positive α-cells was increased (Fig. 5A). No TUNEL or Ki-67 positive nuclei were detected in the islets. Human
islets that were incubated with HFS + Resv exhibited islet morphology similar to control islets. Insulin secretion was increased 2.6-fold with HFS and 6.2-fold with HFS + Resv, and treatment with EX-527, a selective SIRT1 inhibitor, significantly decreased insulin secretion (Fig. 5B). This indicates that the increase in insulin secretion observed with resveratrol treatment is mediated through SIRT1. Additionally, resveratrol treatment resulted in a significant increase in the mRNA expression of PDX1 (Fig. 5C), NKX6-1 (Fig. 5D), FOXO1 (Fig. 5E), and SIRT1 (Fig. 5F). When human islets were treated with EX-527, all of these transcription factors were expressed at levels similar to that of the control group, confirming that the effect of resveratrol in increasing β-cell specific transcription factors in human islets is mediated, at least in part, through SIRT1.

Identification of PC1/3 and GLP-1 in α-cells. Since we observed a dramatic increase in α-cell number in HFS compared to SD, we closely examined the α-cell compartment. Glucagon, which functions to maintain fasting glucose levels by stimulating hepatic glucose production, is produced in α-cells resulting from the enzymatic cleavage of proglucagon by prohormone convertase (PC)2 (30). The glucagon-positive cells in monkey islets co-stained with PC2, as expected (data not shown), and additionally, expressed PC1/3 (Fig. 6A). Proglucagon is also produced in L-cells of the intestine and taste cells in taste buds, and expression of PC1/3 in those cells leads to glucagon-like peptide (GLP)-1 production (22,31). The α-cells in our monkeys expressed GLP-1 (Fig. 6B). There was a significant increase in the amount of GLP-1 staining with HFS because of the increased number of α-cells (Fig. 6C). While PC1/3, as expected, was also present in some insulin-containing cells, GLP-1, similar to glucagon, never co-localized with insulin. The presence of PC1/3 and GLP-1 has been reported in human pancreatic islet cells,
including those from T2DM patients (32). We also detected PC1/3 (Fig. 7A) and GLP-1 (Fig. 7B) immunostaining in α-cells of human pancreas.

**GLP-1 secreted from islets is biologically active.** As we did not have access to fresh monkey islets to ascertain if the GLP-1 present in primate islets is biologically active, freshly isolated human islets were utilized. GLP-1 was detectably secreted into culture medium after 1 hour from as little as 20 human islets (Fig. 7C). In order to determine whether the GLP-1 in islets is biologically active, we extracted total islet protein, measured GLP-1 by ELISA, and normalized it to protein content. The extract was then diluted to give the indicated concentrations of GLP-1 and added to Chinese hamster ovary (CHO) cells and CHO cells stably transfected with GLP-1 Receptor (CHO-GLP-1R). Non-transfected CHO cells did not respond to GLP-1 treatment as measured by a direct cAMP assay (Fig. 7D). However, CHO-GLP-1R cells responded to recombinant GLP-1 and islet extract GLP-1 in a dose dependent manner. Islet extracted GLP-1 actually resulted in a significant increase in cAMP levels (Fig. 7D), demonstrating that GLP-1 present in human islets, and presumably monkey islets, is biologically active.
DISCUSSION

After 24 months on a HFS diet, monkeys had significant weight gain, increased serum insulin levels and insulin AUC following an intravenous glucose challenge, and decreased insulin sensitivity. Moreover, significant changes in islet morphology as a result of a HFS diet, independent of dysglycemia, were also present. Hyperglycemia or the diabetic state itself was not a secondary cause of these intra-islet cellular changes. Most notably, the α-/β-cell ratio was significantly altered due to decreased numbers of insulin-containing cells and increased numbers of glucagon- and GLP-1- containing cells, while total islet size was unaltered. These morphological changes are similar to those observed in monkeys that spontaneously developed T2DM (Fig. 1C), in vervet monkeys administered an 18-month atherogenic diet (33), and in the pathologies of diabetic human pancreata (34). Additionally, a HFS diet resulted in the depletion of β-cell specific transcription factors, FOXO1, NKX6-1, NKX2-2, and PDX1. Remarkably, monkeys given resveratrol supplementation in addition to a HFS diet had islets that were similar in morphology to SD and maintained the critical transcription factors. Resveratrol’s effect was independent of any effect it may have on insulin-mediated glucose uptake, i.e. peripheral insulin sensitivity, because it did not prevent the decline in insulin sensitivity due to the HFS diet.

There are two possibilities for the increase in α-/β-cell ratio observed with HFS monkeys. The first is that β-cells underwent apoptosis and α-cells proliferated but we did not capture either phenomenon because of the brevity of both. One possible signal for α-cell mitosis is that the neighboring β-cells act as brakes on α-cell turnover and this brake is lifted once a neighboring β-cell undergoes apoptosis. Additionally, apoptotic β-cells may shed microparticles/products that cause proliferation of neighboring α-cells. Indeed, apoptosis of β-cells in rodents stimulates proliferation of neighboring cells (35) and insulin itself is trophic in α-cell lines (36).
A decrease in β-cell mass has also been reported in humans with T2DM, and this was associated with an increase in islet amyloid deposition and β-cell apoptosis (37,38). Baboons, which serve as another model for T2DM (39), also exhibit severe islet amyloidosis that is associated with increased β-cell apoptosis and decreased relative β-cell volume as well as α-cell replication and hypertrophy and increased relative α-cell volume (40). The increased α-cell proliferation correlated with hyperglucagonemia and hyperglycemia, neither of which was observed in our monkeys after 24 month on a HFS diet.

A second possibility for the islet findings in HFS monkeys is that β-cells dediffernetiated and became α-cells, thus explaining how islet size was unaltered. Our findings resemble the phenotype seen in transcription factor forkhead box O1 (FOXO1)-null mice in that those mice, placed under metabolic stress, had reduced β-cell numbers due to dedifferentiation, not death, and some dedifferentiated cells became α-cells (26). We suggest that loss of NKX6-1 and PDX1 due to depletion of FOXO1 lifted the brake on repression of glucagon transcription and as a consequence, β-cells, once dedifferentiated, became α-cells. Single human β-cells normally express the glucagon gene, albeit at low levels compared to the insulin gene (41). In no instance did we find co-expression of insulin and glucagon or glucagon and NKX6-1, illustrating that regression of β-cells to a non-β-cell phenotype is necessary prior to conversion to α-cells. We conclude that unremitting hyperstimulation due to HFS food consumption, and not dysglycemia, is the so-called ‘Metabolic Stress’ that causes depletion of FOXO1 and loss of β-cell phenotype.

β-cell loss of FOXO1, NKX6-2, and PDX1 did not occur with HFS consumption when resveratrol was added to the diet. Similar effects have been described in vitro where resveratrol treatment of insulinoma INS-1E cells and human islets resulted in the up-regulation of key genes for β-cell function, including PDX1, ultimately potentiating glucose-stimulated insulin secretion.
We also found that resveratrol treatment resulted in a significant increase in PDX1, NKX6-1, and FOXO1 mRNA expression in human islets incubated under HFS conditions. The increase in β-cell transcription factors was also associated with an increase in insulin secretion, as HFS + Resv treated islets secreted insulin at levels 6.2-fold greater than control and 2.4-fold greater than HFS alone.

GLP-1 is a hormone with pleiotropic effects that helps maintain blood glucose homeostasis. It is a powerful stimulant to insulin secretion in a glucose-dependent manner (43), increases proinsulin synthesis (44), modulates insulin sensitivity (45), and, in rodents, it increases β-cell turnover (46). Additionally, glucagon secretion is inhibited by insulin (47) and by GLP-1 independently of insulin (48). We suggest that increased α-cell-derived GLP-1 promoted enhanced glucose-mediated insulin secretion and contributed to suppression of glucagon secretion in HFS monkeys. This allowed the remaining β-cells to secrete sufficient insulin to maintain euglycemia and suppress glucagon secretion. This mechanism would be successful as long as adequate numbers of β-cells remained. Eventually β-cell numbers would have declined to a limiting amount and circulating glucagon levels would rise due to lack of sufficient insulin for inhibition of secretion. At this time dysglycemia would become evident.

While non-human primate studies are crucial to more accurately elucidate the pathogenesis of T2DM in humans, several limitations are evident due to the nature of this model. In the current study, none of the monkeys in the HFS cohort developed overt diabetes, so islets from monkeys under metabolic stress were compared to those from monkeys that spontaneously developed diabetes to show increasing progression of β-cell depletion. Additionally, we do not know if the α-/β-cell ratio seen with HFS would revert to that of SD if the animals were returned to a healthy standard diet, so we cannot attest to the adaptability of α-cells once metabolic stress
is alleviated. Finally, while we show that daily resveratrol supplementation prevented islet changes in the presence of a HFS diet, we were unable to show the biochemical pathway(s) by which resveratrol was protective. Its effects may be through activation of AMPK or Sirtuins and thus FOXO1 (49,50), through inhibition of phosphodiesterases in β-cells (51), or a combination of many pathways. In human islets we were able to show that blocking SIRT1 prevented the resveratrol-induced increase in insulin secretion and upregulation of PDX1, NKX6-1, FOXO1 and SIRT1 mRNA expression. This suggests that the positive effects of resveratrol on β-cell function in human islets are mediated through SIRT1.

This study was carried out in adult primates and has direct relevance to the human population that is currently facing a diabetic epidemic due to obesity. Screening patients for early T2DM and pre-diabetes is a worthy goal in order to aggressively treat and preserve β-cell function (52,53). We submit, however, that islet changes occur before overt evidence of β-cell compromise and before any dysglycemia are uncovered with usual testing such as fasting glucose levels and hemoglobin A1c measurements. While lifestyle interventions and pharmacotherapy to maintain normal glucose homeostasis and prevent conversion of pre-diabetes to diabetes (54) are laudatory, they are expensive, require intense input from healthcare providers, and need to be persistent. They may also be too late because morphological changes causing predisposition to diabetes could have already occurred in islets. Addition of resveratrol and resveratrol-containing foods to one’s daily diet may be a simple, inexpensive way to protect β-cells.
ACKNOWLEDGEMENTS

This work was supported by the Intramural Research Program of the National Institute on Aging (NIA) and a grant from the Office of Dietary Supplements awarded to Kevin J. Pearson. Wook Kim is supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) and funded by the Ministry of Education, Science, and Technology (2012R1A1A1041352) and the new faculty research fund of Ajou University. Maire E. Doyle is funded by the Juvenile Diabetes Research Foundation and The Sanford Project, Sioux Falls, SD.

No potential conflicts of interest relevant to this article were reported.

J.L.F. designed and performed experiments, analyzed data, and wrote the manuscript. Y-K.S., W.K., S.M.K-W, I.G-M, and O.D.C. designed and performed experiments and analyzed data. M.S. and R.M. developed and performed the assays to determine serum resveratrol levels. K.F. and S.K.G. analyzed data. M.E.D. was responsible for procuring human islets from the IIDP and for the treatment of human islets. K.J.P, J.A.M., and R.dC. contributed to the design, execution, and analysis of experiments. J.M.E. contributed to the design of experiments, interpretation of data, and writing of the manuscript. All authors edited and reviewed the manuscript. J.M.E. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

We would like to thank the animal care staff at the NIH Animal Center, Edward Tilmont, Joanne Allard, Theresa Ward, Kaitlyn Lewis, Caitlin Younts, and our veterinarian Dr. Rick Herbert. We would also like to thank Hyekyung Yang for her assistance with processing human islets for staining. We are grateful to Fred E. Indig at NIA for his invaluable contributions with confocal imaging and to DSM Nutritional Products for providing ResVida (resveratrol).
REFERENCES


Table 1

Monkey characteristics and hormone levels at baseline (0 months) and after (24 months) indicated diets

<table>
<thead>
<tr>
<th>SD (n=4)</th>
<th>HFS (n=10)</th>
<th>HFS+Resv (n=10)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0 months</td>
<td>24 months</td>
</tr>
<tr>
<td>Age (yr)</td>
<td>9.8±0.8</td>
<td>12.8±1.1</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>12.98±1.21</td>
<td>13.49±1.31</td>
</tr>
<tr>
<td>Fasting Glucose (mg/dl)</td>
<td>58.77±1.14</td>
<td>42.33±2.31</td>
</tr>
<tr>
<td>Fasting Insulin (µU/ml)</td>
<td>27.34±6.61</td>
<td>89.15±58.92</td>
</tr>
<tr>
<td>Insulin AUC after IVG</td>
<td>6254.00±1081.09</td>
<td>6484.67±1851.36</td>
</tr>
<tr>
<td>ISI (10^-5)</td>
<td>0.84±0.17</td>
<td>0.82±0.15</td>
</tr>
<tr>
<td>Fasting Glucagon (pg/ml)</td>
<td>31.87±5.59</td>
<td>46.33±17.62</td>
</tr>
</tbody>
</table>

SD, standard diet; HFS, high fat/high sugar diet + placebo; HFS+Resv, high fat/high sugar diet + resveratrol; AUC, area under the curve; IVG, intravenous glucose challenge; ISI, insulin sensitivity index. Data are shown as the mean ± SEM. Compared to baseline within each group: *p<0.05, **p<0.01.
FIGURE LEGENDS

Figure 1: HFS diet-induced morphological changes in pancreatic islets. A and B: Glucose (A) and insulin (B) levels at fasting and following intravenous glucose challenge (300 mg/kg) before (0, open bars) and after (24, closed bars) 24 months on SD (blue circle, n=4), HFS (red square, n=10), or HFS+Resv (green triangle, n=10) diet interventions in adult rhesus monkeys. C: Representative images of immunostaining for insulin (red), glucagon (green), and TO-PRO-3 (blue) in islets of monkeys after 24 months on the indicated diet intervention, and in two non-study monkeys that spontaneously developed T2DM. Scale bar = 20 µm. D-F: Quantification of total islet size (D), β-cell mass (insulin) (E), and α-cell mass (glucagon) (F). G: Ratio of α-cell mass to β-cell mass. H and I: The percentage of cells that were insulin positive (H) and glucagon positive (I) in each islet. Data are shown as the mean ± SEM and *p<0.05.

Figure 2: Lack of apoptosis in β-cells, mitosis in α-cells, or changes in the number of other intra-islet hormone cell types. A: Immunostaining for insulin (green), glucagon (blue), and phosphorylated Bad (P-Bad, red) in islets of monkeys after 24 months on SD (top panel), HFS (middle panel), or HFS+Resv (bottom panel) diets. Scale bar = 20 µm. B: Ki-67 (red), glucagon (green), and TO-PRO-3 (blue) staining in islets of monkeys after 24 months on the indicated diets. Red arrows indicate Ki-67 positive cells that were detected in non-endocrine tissue. Ki-67 staining in duodenum was used as a positive control. Scale bar = 20 µm. C: Quantification of somatostatin (white bars) and pancreatic polypeptide (black bars) cell mass in the different diet interventions. Data are shown as the mean ± SEM.
Figure 3: Decreased P-IR and total FOXO1 levels in a HFS diet. A: Immunostaining for insulin (green), glucagon (blue), and tyrosine phosphorylated insulin receptor (P-IR, red) in islets of monkeys after 24 months on SD (top panel), HFS (middle panel), or HFS+Resv (bottom panel) diets. Scale bar = 20 µm. B: Quantitation of signal intensity for P-IR. Data are shown as the mean ± SEM and *p<0.05. C: Immunostaining for insulin (green), TO-PRO-3 (blue), and total FOXO1 (red) in islets of monkeys after 24 months on a SD (top panel), HFS (middle panel), or HFS+Resv (bottom panel) diets. Scale bar = 20 µm. D and E: Quantitation of signal intensity (D) and mRNA levels (E) for FOXO1. Data are shown as the mean ± SEM and *p<0.05.

Figure 4: Decreased nuclear expression of NKX6-1, NKX2-2, and PDX1 following a HFS diet. A: Immunostaining for insulin (green), glucagon (blue), and NKX6-1 (red) in monkeys after 24 months on the indicated diet. The islets from different HFS monkeys are shown in order of declining β-cell numbers (bottom panel), while the red arrows indicate depletion of nuclear NKX6-1 in insulin-expressing cells. Scale bar = 20 µm. B and C: Quantitation of signal intensity (B) and mRNA levels (C) for NKX6-1. Data are shown as the mean ± SEM and *p<0.05. D: Immunostaining for insulin (green), glucagon (blue), and NKX2-2 (red) in islets of monkeys after 24 months on SD (top panel), HFS (middle panel), or HFS+Resv (bottom panel) diets. Scale bar = 20 µm. E and F: Quantitation of signal intensity (E) and mRNA levels (F) for NKX2-2. Data are shown as the mean ± SEM and *p<0.05. G: Quantitation of mRNA levels for PDX1. Data are shown as the mean ± SEM and *p<0.05.
Figure 5: Resveratrol protects islet morphology, increases insulin secretion, and increases mRNA expression of PDX1, NKX6-1, FOXO1, and SIRT1 in human islets. A: Immunostaining for insulin (green), glucagon (red), and TO-PRO-3 (blue) in human islets. Scale bar = 20 µm B: Insulin secretion per human islet after 24 hours in low glucose (Control), high glucose and palmitate (HFS), HFS and resveratrol (HFS + Resv), or HFS + Resv and a SIRT1 inhibitor (HFS + Resv + EX-527). C-F: Quantitation of mRNA levels for PDX1 (C), NKX6-2 (D), FOXO1 (E), and SIRT1 (F) in human islets after the indicated treatments. Data are shown as the mean ± SEM and *p<0.05, **p<0.01.

Figure 6: Identification of PC1/3 and GLP-1 in monkey islets. A: Immunostaining for insulin (green) and glucagon (blue) and prohormone convertase (PC) 1/3 (red) in SD monkey islets. B: Immunostaining for insulin (green), glucagon (blue), and glucagon-like peptide (GLP) -1 (red) in islets of monkeys after 24 months on SD (top panel), HFS (middle panel), or HFS+Resv (bottom panel) diet interventions. Scale bar = 20 µm. C: Quantitation of signal intensity for GLP-1. Data are shown as the mean ± SEM and *p<0.05.

Figure 7: Secretion of biologically active GLP-1 from human islets. A and B: Immunostaining for insulin (green) and glucagon (blue) along with PC1/3 (red) (A) or GLP-1 (red) (B) in human islets. Scale bar = 20 µm. C: Levels of secreted GLP-1 from medium alone or from 20 human islets into medium over 1 hour as measured by ELISA. D: cAMP concentrations following treatment of CHO/K1 (black bars) and CHO-GLP-1 Receptor (GLP-1R, white bars) cells with either increasing concentration of recombinant GLP-1 protein (GLP-1) as a positive control or
GLP-1 extracted from islets (Islet extract). Data are shown as the mean ± SEM from at least three independent experiments and *p<0.05.
Figure 1: HFS diet-induced morphological changes in pancreatic islets. A and B: Glucose (A) and insulin (B) levels at fasting and following intravenous glucose challenge (300 mg/kg) before (0, open bars) and after (24, closed bars) 24 months on SD (blue circle, n=4), HFS (red square, n=10), or HFS+Resv (green triangle, n=10) diet interventions in adult rhesus monkeys. C: Representative images of immunostaining for insulin (red), glucagon (green), and TO-PRO-3 (blue) in islets of monkeys after 24 months on the indicated diet intervention, and in two non-study monkeys that spontaneously developed T2DM. Scale bar = 20 µm. D-F: Quantification of total islet size (D), β-cell mass (insulin) (E), and α-cell mass (glucagon) (F). G: Ratio of α-cell mass to β-cell mass. H and I: The percentage of cells that were insulin positive (H) and glucagon positive (I) in each islet. Data are shown as the mean ± SEM and *p<0.05.
Figure 2: Lack of apoptosis in β-cells, mitosis in α-cells, or changes in the number of other intra-islet hormone cell types. A: Immunostaining for insulin (green), glucagon (blue), and phosphorylated Bad (P-Bad, red) in islets of monkeys after 24 months on SD (top panel), HFS (middle panel), or HFS+Resv (bottom panel) diets. Scale bar = 20 µm. B: Ki-67 (red), glucagon (green), and TO-PRO-3 (blue) staining in islets of monkeys after 24 months on the indicated diets. Red arrows indicate Ki-67 positive cells that were detected in non-endocrine tissue. Ki-67 staining in duodenum was used as a positive control. Scale bar = 20 µm. C: Quantification of somatostatin (white bars) and pancreatic polypeptide (black bars) cell mass in the different diet interventions. Data are shown as the mean ± SEM.

164x276mm (300 x 300 DPI)
Figure 3: Decreased P-IR and total FOXO1 levels in a HFS diet. A: Immunostaining for insulin (green), glucagon (blue), and tyrosine phosphorylated insulin receptor (P-IR, red) in islets of monkeys after 24 months on SD (top panel), HFS (middle panel), or HFS+Resv (bottom panel) diets. Scale bar = 20 µm. B: Quantitation of signal intensity for P-IR. Data are shown as the mean ± SEM and *p<0.05. C: Immunostaining for insulin (green), TO-PRO-3 (blue), and total FOXO1 (red) in islets of monkeys after 24 months on a SD (top panel), HFS (middle panel), or HFS+Resv (bottom panel) diets. Scale bar = 20 µm. D and E: Quantitation of signal intensity (D) and mRNA levels (E) for FOXO1. Data are shown as the mean ± SEM and *p<0.05.
Figure 4: Decreased nuclear expression of NKX6β1, NKX2β2, and PDX1 following a HFS diet. A: Immunostaining for insulin (green), glucagon (blue), and NKX6β1 (red) in monkeys after 24 months on the indicated diet. The islets from different HFS monkeys are shown in order of declining β-cell numbers (bottom panel), while the red arrows indicate depletion of nuclear NKX6-1 in insulin-expressing cells. Scale bar = 20 µm. B and C: Quantitation of signal intensity (B) and mRNA levels (C) for NKX6-1. Data are shown as the mean ± SEM and *p<0.05.

D: Immunostaining for insulin (green), glucagon (blue), and NKX2β2 (red) in islets of monkeys after 24 months on SD (top panel), HFS (middle panel), or HFS+Resv (bottom panel) diets. Scale bar = 20 µm. E and F: Quantitation of signal intensity (E) and mRNA levels (F) for NKX2-2. Data are shown as the mean ± SEM and *p<0.05. G: Quantitation of mRNA levels for PDX1. Data are shown as the mean ± SEM and *p<0.05.
Figure 5: Resveratrol protects islet morphology, increases insulin secretion, and increases mRNA expression of PDX1, NKX6-1, FOXO1, and SIRT1 in human islets. A: Immunostaining for insulin (green), glucagon (red), and TO-PRO-3 (blue) in human islets. Scale bar = 20 µm B: Insulin secretion per human islet after 24 hours in low glucose (Control), high glucose and palmitate (HFS), HFS and resveratrol (HFS + Resv), or HFS + Resv and a SIRT1 inhibitor (HFS + Resv + EX-527). C-F: Quantitation of mRNA levels for PDX1 (C), NKX6-2 (D), FOXO1 (E), and SIRT1 (F) in human islets after the indicated treatments. Data are shown as the mean ± SEM and *p<0.05, **p<0.01.
Figure 6: Identification of PC1/3 and GLP-1 in monkey islets. A: Immunostaining for insulin (green) and glucagon (blue) and prohormone convertase (PC) 1/3 (red) in SD monkey islets. B: Immunostaining for insulin (green), glucagon (blue), and glucagon-like peptide (GLP) 1 (red) in islets of monkeys after 24 months on SD (top panel), HFS (middle panel), or HFS+Resv (bottom panel) diet interventions. Scale bar = 20 µm. C: Quantitation of signal intensity for GLP-1. Data are shown as the mean ± SEM and *p<0.05.
Figure 7: Secretion of biologically active GLP-1 from human islets. A and B: Immunostaining for insulin (green) and glucagon (blue) along with PC1/3 (red) (A) or GLP-1 (red) (B) in human islets. Scale bar = 20 µm. C: Levels of secreted GLP-1 from medium alone or from 20 human islets into medium over 1 hour as measured by ELISA. D: cAMP concentrations following treatment of CHO/K1 (black bars) and CHO-GLP-1 Receptor (GLP-1R, white bars) cells with either increasing concentration of recombinant GLP-1 protein (GLP-1) as a positive control or GLP-1 extracted from islets (Islet extract). Data are shown as the mean ± SEM from at least three independent experiments and *p<0.05.
Supplemental Figure 1

A) Age (yr)
B) Weight (kg)
C) Fasting Glucose (mg/dL)
D) Fasting Insulin (µU/ml)
E) Insulin AUC after IVG
F) ISI (10⁻³)
G) Fasting Glucagon (pg/ml)
Supplemental Figure 1: Heterogeneity of monkey characteristics and hormone levels. A-G: Box-and-Whisker plots showing monkey heterogeneity at 0 and 24 months on the indicated diets in age (A), weight (B), fasting glucose (C), fasting insulin (D), insulin area under the curve (AUC) after intravenous glucose challenge (IVG) (E), insulin sensitivity index (ISI) (F), and fasting glucagon (G).